

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 November 2004 (25.11.2004)

PCT

(10) International Publication Number
WO 2004/100797 A1

(51) International Patent Classification⁷: **A61B 10/00**,
17/00, 19/08

Benedict, Marie [NL/NL]; Stuurmankade 144, NL-1019
WB Amsterdam (NL).

(21) International Application Number:
PCT/NL2004/000353

(74) Agent: VAN WESTENBRUGGE, Andries et al.; Ned-
erlandsch Octrooibureau, Scheveningseweg 82, P.O. Box
29720, NL-2502 LS The Hague (NL).

(22) International Filing Date: 19 May 2004 (19.05.2004)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(25) Filing Language: Dutch

(26) Publication Language: English

(30) Priority Data:
1023462 19 May 2003 (19.05.2003) NL

(71) Applicant (*for all designated States except US*):
DOORZAND TROCAR PROTECTOR B. V. [NL/NL];
Stuurmankade 144, NL-1019 WB Amsterdam (NL).


(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **DOORSCHODT,**

[Continued on next page]

(54) Title: INSERTION SLEEVE ASSEMBLY



(57) Abstract: Insertion sleeve assembly
consisting of a sleeve and an insertion instrument.
The sleeve is made of a material that collapses
after having been introduced into the body and
on withdrawal of the biopsy needle. Cells are
captured as a result. Such a material can be a
material that is relatively rigid at relatively low
temperature and low humidity outside the body
and becomes soft on insertion into the body
under the influence of temperature and moisture.
The insertion sleeve can be provided with a
number of break locations so that no stress can
arise between the various parts of the body after
withdrawal of the biopsy needle.

WO 2004/100797 A1



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

Insertion sleeve assembly

The present invention relates to an insertion sleeve assembly comprising an insertion instrument for performing a medical operation and a sleeve of bio-absorbable material
5 guiding said instrument.

Such an assembly is disclosed in Netherlands Patent Application 9302140. In this application an insertion sleeve assembly is described with reference to a biopsy needle assembly. Here the insertion instrument is the biopsy needle and after a sample has been taken this biopsy needle is withdrawn and the sleeve remains behind. Because of the bio-
10 absorbable nature thereof, this will disappear by itself after some time.

However, it has been found that when the biopsy needle is withdrawn cells from the possibly infected tissue are spread along the inside of the sleeve by the biopsy needle as it is withdrawn. The insertion sleeve must have a certain rigidity in order to be able to be introduced into the body together with the biopsy needle. As a result of the same rigidity,
15 the sleeve remains intact for some time after the needle has been withdrawn until it dissolves. If the sleeve were to be made of a softer material, fitting it on the biopsy needle would not be possible without it rolling up and the like.

It has been found that the risk of infection remains while the sleeve is intact and that the risk of dissemination of undesirable cell material from inside the body into the skin is
20 real.

The aim of the present invention is to avoid this disadvantage.

This aim is realised with an insertion sleeve assembly as described above in that said sleeve is made of a material that is relatively rigid outside the body and becomes softer after introduction into the body and collapses onto itself when the instrument is withdrawn.

25 According to the present invention the sleeve is made such that this is, on the one hand, sufficiently rigid to be able to be introduced into the body together with the biopsy needle without rolling up and, on the other hand, is sufficiently soft to collapse after the biopsy needle has been removed. Consequently it is possible, for example, for tumour cells to be captured by the sleeve when a biopsy needle is withdrawn. Optionally, the sleeve can
30 close off completely when it collapses.

Such characteristics can be obtained in many ways known in the state of the art.

According to an advantageous embodiment of the invention, the sleeve is made of a material that is relatively rigid at temperatures below 30 °C and in an environment free

from moisture. However, when the temperature is raised in combination with a high moisture content, such as when the sleeve is inserted in the human body, the material that is used according to a preferred embodiment will rapidly become soft, as a result of which the sleeve will not remain in place without the support of the biopsy needle. This means that
5 with this material relatively rapid insertion of the sleeve in combination with a needle is possible without the risk of rolling up, but that, on the other hand, the sleeve collapses immediately when a needle is withdrawn.

Many materials have the characteristics described above. A few examples thereof are poly-ε-caprolactone-DL-lactide copolymer; ε-caprolactone; D-lactide; L-lactide; DL-lactide
10 and poly(DL-lactide-co-glycolide).

Particularly good results are obtained with a material consisting of a combination of polyglycolide (30 - 50 % (m/m)), polylactic acid (25 - 50 % (m/m)) and caprolactone (4 - 25 % (m/m)).

According to an advantageous embodiment of the invention, the material of the
15 sleeve is made such that the outside thereof has staunching properties. As a result, the effect of a haemorrhage can be prevented. Good adhesion between the exterior of the sleeve and the surrounding tissue is provided by absorbing properties.

Furthermore, it has been found that when a sleeve is inserted through various organs appreciable stresses are exerted on the human body in the period before said sleeve
20 dissolves completely. After all, various parts of the human body move relative to one another. Organs that are in the abdominal cavity are one example. The sleeve still has an appreciable strength immediately after the insertion instrument has been removed or, alternatively, immediately after fitting the sleeve, so that in the case of such a movement of parts of the human body relative to one another stresses can arise that are undesirable and
25 can lead to damage to the organs but also to undesired displacement of the sleeve.

This applies in particular if there is a tumour close to the end of the sleeve, there being a risk of metastases as a result of displacement of the sleeve.

A further aim of the present invention is to overcome this disadvantage and to provide an insertion sleeve assembly that can be used safely.

30 This further aim is realised with an insertion sleeve as described above in that said sleeve is provided with at least two break locations, the minimal distance from the distal break point to the distal end being 15 mm and the distance between said break locations being less than 20 mm.

As a result of providing the break locations, breaks will occur when a minimum stress is exceeded, which minimum stress, of course, is so chosen that no damage whatsoever to the organs takes place or, alternatively, no movement whatsoever of the sleeve is caused under this stress. This break has no further consequence whatsoever, but
5 prevents further stress. The break locations or points are provided such that the break takes place outside the organ in which the medical intervention has been carried out. That is to say, the minimum distance described above is essential for proper functioning thereof. After all, the stresses mentioned above will not arise in the organ concerned, for example breast or prostate, and it is not desirable that the sleeve breaks in the organ, as a result of
10 which part of the sleeve moves out of the organ with all the harmful associated consequences, such as infection.

It is pointed out that an insertion sleeve provided with a break point or location close to the end thereof is disclosed in US 4 838 280. The aim of the structure described in the US patent is precisely to allow a break to occur within the organ concerned.

15 As insertion instrument is understood to be any medical instrument that can be used in combination with a sleeve. Apart from the biopsy needle described above, a wide variety of instruments that are used for so-called exploratory surgery fall under this definition.

According to an advantageous variant of the invention, there are at least five break locations or points.

20 The sleeve can be made in any way in order to function in an optimum manner. For instance, it is possible to make this from a single material that is provided with thinner regions in order to create the break locations.

It is furthermore possible to build up the sleeve from a number of layers of material. In particular, it is possible to produce this from a relatively weak material and to provide it
25 with reinforcing rings. On the one hand, adequate strength and, on the other hand, adequate flexibility are achieved by the use of these rings. These rings can be circular rings, but can also be made as a continuous spiral.

It must be understood that the characteristics described above with regard to the sleeve being breakable can also be employed with a sleeve made of another material, that is
30 to say a material that is soft and/or rigid under all conditions.

Moreover, the sleeve can be so made that this has particular properties. Examples thereof are, apart from being bio-absorbable, the use of material with a blood-staunching

effect and material that counteracts infection. Materials used for the sleeve can be polyglucolactate, caprolactone, polyglycolide and combinations thereof.

According to a further advantageous embodiment of the invention, the distance between the break locations is 3 - 7 mm.

5 The sleeve has a wall thickness of preferably between 0.5 and 1.5 mm.

The invention will be explained in more detail below with reference to an illustrative embodiment shown in the drawing. In the drawing:

Fig. 1 shows the insertion sleeve assembly according to the present invention constructed as a biopsy needle assembly;

10 Fig. 2 shows the construction according to Fig. 1 immediately after removal of the biopsy needle; and

Fig. 3 shows the construction according to Fig. 2 after break has taken place.

In the drawing an insertion sleeve assembly is shown by 10. This consists of a sleeve 12 and an instrument, such as a biopsy needle 3, to be inserted therein. Sleeve 12 is provided with a stop 11. Sleeve 12 is introduced together with needle 13 into the body in order to take a sample of section 13 of organ 9. Sleeve 12 provides permanent protection in order to prevent infection or other undesired reactions on withdrawal of needle 3. After the removal of needle 3, the sleeve will (partially) collapse (Fig. 2). Because this sleeve is made of bio-absorbable material, such as polyglucolactate or caprolactone or a combination thereof, the sleeve 12 will disappear after some time has elapsed.

As can be seen from Figs 1 and 2, the sleeve 12 has a number of break points extending all round, which are indicated by 8. The mutual spacing between the break points 8 is approximately 5 cm. The sleeve is made up of a layer of film material 6 reinforced by a spiral 7.

25 The situation after insertion of the assembly and when taking the sample in organ 13 is shown in Fig. 1. The sleeve 12 is relatively rigid when it is inserted. As a result, it can be introduced at the same time as the needle 3 without the risk of rolling up. The situation after the removal of biopsy needle 3 is shown in Fig. 2. Here the sleeve remains in the body. The material of the sleeve will become soft as a result of absorbing moisture from the surrounding body tissue and the rising temperature, as a result of which, as shown, the sleeve collapses and possibly sticks to itself internally. A somewhat flexible connection between organ 9, cavity 15 and skin 14 is produced by the flexible film 6 and the rings or spiral 7. By this means it is possible for small mutual movements to be absorbed. However,

30

if these movements become too large, a tensile or compressive stress will be produced between organ 9 and other parts of the human body. Were the sleeve not to break, there is the risk that some organs are displaced and this displacement is sometimes not reversed by itself. The break points 8 act to prevent this excessive stress and thus damage. These break
5 locations provide for breakage of the various parts of sleeve 12. One example of such a break is shown in Fig. 3. It must be understood that as a result of the relatively rigid solid nature of organ 9, break will always occur outside this organ, such as, for example, in the cavity 15. In general, break will occur at the interface between the organ 13 and cavity 15 or, alternatively, between cavity 15 and skin 14. It will be understood that movement
10 between organs can also occur in other parts of the human body and break will then occur at the transition between two organs where mutual movement takes place.

Although the invention has been described above with reference to a preferred embodiment, it will be understood by those skilled in the art that numerous modifications can be made thereto without going beyond the scope of the present invention as described
15 in the appended claims.

Claims

1. Insertion sleeve assembly (10) comprising an insertion instrument (3) for performing a medical operation and a sleeve (12) of bio-absorbable material guiding said instrument,
5 characterised in that said sleeve is made of a material that is relatively rigid outside the body and becomes softer after introduction into the body and collapses onto itself when the instrument is withdrawn.
2. Insertion sleeve assembly according to Claim 1, wherein said sleeve (12) is made of a
10 material that is relatively rigid at temperatures below 30 °C and not in contact with water and is relatively soft at temperatures between 35 °C and 40 °C and in contact with moisture.
3. Insertion sleeve assembly according to one of the preceding claims, wherein said
15 material comprises a material from the group comprising: polyglycolide; poly-ε-caprolactone-DL-lactide copolymer; ε-caprolactone; D-lactide; L-lactide; DL-lactide and poly(DL-lactide-co-glycolide).
4. Insertion sleeve according to one of the preceding claims, wherein said material
20 comprises a combination of polyglycolide (30 - 50 % by wt), polylactic acid (25 - 50 % by wt) and caprolactone (4 - 25 % by wt).
5. Insertion sleeve assembly according to one of the preceding claims, wherein said
25 sleeve has blood-staunching properties on the outside.
6. Insertion sleeve assembly according to one of the preceding claims, wherein said
sleeve is provided with at least two break points (8), the minimal distance from the distal
break point to the distal end being 10 mm and the distance between said break locations
being less than 20 mm.
30
7. Insertion sleeve assembly according to Claim 6, having at least five break locations.

8. Insertion sleeve assembly according to one of the preceding claims in combination with Claim 6, wherein said sleeve is designed for direct contact with said insertion instrument and the body.
- 5 9. Insertion sleeve assembly according to Claim 8, wherein the distance between said break locations is 3 - 10 mm.
- 10 10. Insertion sleeve assembly according to one of the preceding claims in combination with Claim 6, wherein said sleeve comprises a continuous base sleeve of flexible material and a number of rings (7) arranged around it.
11. Insertion sleeve assembly according to Claim 10, wherein said sleeve has a wall thickness of 0.1 - 1.5 mm.
- 15 12. Insertion sleeve according to Claim 10 or 11, wherein said rings are made of a blood-staunching material.

Fig 2





Fig 3



INTERNATIONAL SEARCH REPORT

Application No
PCT/NL2004/000353

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61B10/00 A61B17/00 A61B19/08		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61B		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2003/050664 A1 (SOLEM) 13 March 2003 (2003-03-13) abstract; figures paragraph '0033!	1, 3, 4
A	NL 9 302 140 A (DOORSCHODT) 3 July 1995 (1995-07-03) the whole document	1, 4
A	US 4 838 280 A (HAAGA) 13 June 1989 (1989-06-13) abstract; figures column 7, lines 11-30	1
A	EP 1 070 514 A (NUCLETRON B.V.) 24 January 2001 (2001-01-24) abstract; claims 4,9; figures 1a-1g column 4, line 57 - column 5, line 35	1, 3
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *G* document member of the same patent family		
Date of the actual completion of the international search 10 August 2004		Date of mailing of the international search report 18/08/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Compos, F

INTERNATIONAL SEARCH REPORT

Application No
PC 1/NL2004/000353

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>US 5 976 146 A (OGAWA ET AL.) 2 November 1999 (1999-11-02) abstract; figures column 30, lines 35-55</p>	1

INTERNATIONAL SEARCH REPORT

 Application No
 PCT/NL2004/000353

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2003050664	A1	13-03-2003	SE 523902 C2 CA 2459956 A1 WO 03022158 A1 EP 1429661 A1 SE 0102968 A	01-06-2004 20-03-2003 20-03-2003 23-06-2004 08-03-2003
NL 9302140	A	03-07-1995	NONE	
US 4838280	A	13-06-1989	CA 1313100 C DE 3917051 A1 FR 2631811 A1 GB 2218910 A, B IT 1231691 B US 5330445 A US 5447502 A US 4936835 A US 5573518 A US 5080655 A US 5195988 A US 5254105 A	26-01-1993 07-12-1989 01-12-1989 29-11-1989 19-12-1991 19-07-1994 05-09-1995 26-06-1990 12-11-1996 14-01-1992 23-03-1993 19-10-1993
EP 1070514	A	24-01-2001	DE 60010810 D1 EP 1070514 A1 JP 2001046534 A US 6251060 B1	24-06-2004 24-01-2001 20-02-2001 26-06-2001
US 5976146	A	02-11-1999	JP 11076246 A EP 0890341 A1 JP 11076247 A	23-03-1999 13-01-1999 23-03-1999